BioSpace News Archive

Career Advice

How Companies Use AI to Grade Candidates—and Even Potential Locations

The biopharma industry is moving toward using AI to try to determine how well a given person would perform in a role, with applications that go beyond recruiting.

November 1, 2023
·
5 min read
·
Mollie Barnes
Business

VC Firm Bioluminescence Ventures Launches with $477M in Assets

The biotech venture capital firm, led by former Andreessen Horowitz senior partner Kouki Harasaki, emerged from stealth on Wednesday focused on investing in companies with first-in-class or best-in-class therapies.

November 1, 2023
·
2 min read
·
Tyler Patchen
Policy

FDA Adcomm Sides with Vertex, CRISPR on Safety Testing for SCD Gene Therapy

The regulator’s advisory committee on Tuesday found Vertex Pharmaceuticals and CRISPR Therapeutics’ off-target analysis for its sickle cell disease candidate exa-cel to be sufficient.

November 1, 2023
·
2 min read
·
Tristan Manalac
Policy

FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death

The regulator has released Mersana Therapeutics’ antibody-drug conjugate XMT-2056 from its clinical hold, allowing the biotech to proceed with Phase I studies of the candidate with a lower starting dose.

November 1, 2023
·
2 min read
·
Tristan Manalac
Business

GSK Touts Strong Q3 Performance on the Back of Arexvy, Shingrix Sales

The British biopharma company reported 10% sales growth in the third quarter, driven mainly by robust sales of its respiratory syncytial virus shot Arexvy and shingles vaccine Shingrix.

November 1, 2023
·
2 min read
·
Tristan Manalac
Business

AstraZeneca Drops $245M on Cell and Gene Therapies in Deal with Cellectis

The investment in the French biotech is one of many the pharma giant has made this year to advance cell and gene therapy development. Cellectis shares skyrocketed over 180% in premarket trading Wednesday.

November 1, 2023
·
2 min read
·
Kate Goodwin
Business

GSK Inks $1B Deal Securing Rights to Arrowhead, J&J’s Hepatitis B Drug

The British biopharma and Arrowhead Pharmaceuticals have reached an agreement with J&J’s Janssen to transfer worldwide rights to develop and commercialize JNJ-3989 to GSK.

November 1, 2023
·
2 min read
·
Tyler Patchen
Spexis Announces Changes to the Executive Committee

Spexis AG announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company.

November 1, 2023
·
2 min read
Pharming Group to participate in November 2023 investor conferences

Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of November:.

November 1, 2023
·
1 min read
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

argenx SE announced 20 presentations of clinical trial and real-world data from studies of VYVGART® and VYVGART Hytrulo® in neuromuscular autoimmune disease.

November 1, 2023
·
16 min read